Golimumab
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
Golimumab: From Inflammatory Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Golimumab is a fully human anti-TNF-α monoclonal antibody used for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) based on literature evidence in this pack. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, with 3 clinical trials and 6 publications currently identified, though none directly tests golimumab in this population — evidence is mechanism-based rather than confirmatory.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this pack (no TFDA license on file); literature evidence (PMID 28530020) describes approval for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis (AS/nr-axSpA) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L4 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data is flagged as a data gap in this pack (DG002). However, literature evidence within the pack (PMID 28530020, 20065639) describes golimumab as a fully human IgG1κ monoclonal antibody that binds both soluble and transmembrane TNF-α, blocking its interaction with TNF receptors — the basis for its approved use in rheumatoid arthritis (RA), psoriatic arthritis, axial spondyloarthritis, and (via the IV formulation in some markets) polyarticular juvenile idiopathic arthritis.
Rheumatoid vasculitis (RV) is a severe extra-articular complication of long-standing, seropositive RA, driven by immune-complex-mediated vascular inflammation in which TNF-α is implicated. One case report in this pack (PMID 29075910) notes that RV incidence has declined since the introduction of anti-TNF biologics, supporting the biological plausibility of TNF blockade for RV.
That said, the same evidence pack also contains a countervailing signal: a case report of anti-TNF therapy being associated with paradoxical large-vessel vasculitis (Takayasu’s arteritis, PMID 22999907) arising during treatment. This means the mechanistic direction is not unambiguous — anti-TNF agents can, in rare instances, trigger or unmask vasculitic phenomena rather than suppress them. Combined with the complete absence of RV-specific trials, this uncertainty underlies the L4 evidence level and Hold recommendation.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01579006 | N/A | Completed | 184 | Observational study of tocilizumab (not golimumab) in RA patients with inadequate response to DMARDs; general RA practice patterns, not RV-specific |
| NCT05696106 | N/A | Unknown | 750,000 | Large cohort study on risk of developing a second immune-mediated inflammatory disease (IMID) in patients on biologics; not a golimumab/RV intervention study |
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty; no direct RV or golimumab efficacy data |
Note: None of the identified trials directly evaluates golimumab for rheumatoid vasculitis; all three are graded “C” (low relevance) in the source evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31491879 | 2019 | Network meta-analysis (RCTs) | Int J Mol Sci | Compares golimumab and 4 other TNF inhibitors vs. methotrexate on radiographic joint destruction in RA; not RV-specific |
| 23557513 | 2013 | Review | BMC Medicine | General overview of biologic therapies for autoimmune/rheumatologic disease |
| 27591827 | 2017 | Cohort | Semin Arthritis Rheum | Frequency and causes of end-stage renal disease in RA patients; not golimumab/RV-specific |
| 29075910 | 2018 | Case report | Rheumatol Int | Severe pyoderma gangrenosum/septic arthritis in an RA patient on golimumab; notes RV incidence has declined in the anti-TNF era |
| 22999907 | 2013 | Case report | Joint Bone Spine | Two cases of Takayasu’s arteritis (large-vessel vasculitis) arising during anti-TNF therapy — a paradoxical safety signal |
| 23252659 | 2013 | Case report | Ocul Immunol Inflamm | Golimumab successfully used off-label for Behçet disease-associated uveitis (a different vasculitis-associated condition) |
Taiwan Market Information
Golimumab is currently not marketed in Taiwan (TFDA) per this evidence pack (0 registrations on file). No product license, brand name, or approved-indication text is available.
Safety Considerations
- Drug Interactions: The DDI database records 352 total interactions for golimumab (20 sampled in this pack). Notable Major-level interactions include systemic corticosteroids (Hydrocortisone, Prednisone, Prednisolone, Dexamethasone, Betamethasone, Triamcinolone, Budesonide) — combined immunosuppression/infection risk — as well as Deferiprone and radiolabeled/immunogenic biologics (Iobenguane I-131, Ibritumomab tiuxetan, Tositumomab/Tositumomab I-131). Moderate-level interactions include Rosuvastatin, Simvastatin, Metronidazole, and Tinidazole. Minor-level interactions include zinc salts (sulfate, acetate, gluconate).
Key warnings and contraindications are not available in this evidence pack (TFDA label data flagged as a Blocking data gap, DG001) — refer to the package insert for full safety information.
Other Predicted Indications in This Evidence Pack
This evidence pack (TW-DB06674-multi) contains 5 ranked TxGNN predictions for golimumab. Two other candidates have substantially stronger direct clinical evidence than the top-ranked prediction above and warrant separate attention:
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 3 | Inflammatory spondylopathy | 99.66% | L1 | Proceed with Guardrails | Multiple completed Phase 3 RCTs directly testing golimumab in axial spondyloarthritis/ankylosing spondylitis (e.g. NCT01453725, NCT00265083, NCT03253796); this is a confirmatory extension of an already-approved mechanism, not a novel hypothesis |
| 5 | Polyarticular juvenile rheumatoid arthritis | 99.59% | L1 | Proceed with Guardrails | Two independent Phase 3 RCTs of IV golimumab in pediatric pJIA (NCT02277444 completed n=130; NCT01230827 terminated n=173 — termination reason should be checked for safety signals) |
| 2 | Hypermobility of coccyx | 99.67% | L5 | Hold | No trials, no literature; structural/mechanical condition with no plausible link to TNF-α inhibition — likely knowledge-graph noise |
| 4 | Kummell disease | 99.61% | L5 | Hold | No trials, no literature; ischemic vertebral collapse, not an autoimmune/inflammatory condition — no plausible mechanistic basis |
If the goal is to identify the most actionable repurposing opportunity for golimumab from this pack, inflammatory spondylopathy or polyarticular JIA are better-supported candidates than rheumatoid vasculitis and merit their own dedicated evaluation.
Conclusion and Next Steps
Decision: Hold (for Rheumatoid Vasculitis)
Rationale: Evidence for golimumab in rheumatoid vasculitis is mechanism-based only (L4) — no clinical trial or study directly evaluates this combination, and the pack itself contains a countervailing case report of anti-TNF-associated paradoxical vasculitis, introducing safety uncertainty rather than confidence.
To proceed, the following is needed:
- TFDA label data (key warnings, contraindications) — currently a Blocking data gap (DG001)
- Formal DrugBank MOA confirmation (DG002)
- A dedicated study or registry cohort of RV patients treated with golimumab, given zero direct trials currently exist
- Clarification of the paradoxical vasculitis signal (PMID 22999907) before any safety sign-off
- Separately, consider fast-tracking evaluation of inflammatory spondylopathy and polyarticular JIA from the same pack, given their L1 evidence and existing Phase 3 RCT support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.